Completed PHASE3 INTERVENTIONAL 2-arm NCT00352846

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy

Sponsor: M.D. Anderson Cancer Center

Conditions Lymphoma Non-Hodgkin's Lymphoma

Interventions Calcium Carbonate Vitamin D Zoledronic Acid

Updated 5 times since 2017 Last updated: Jun 20, 2013 Started: Jan 31, 2006 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Lymphoma and Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Novartis

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States